Nonimmune fetal hydrops due to parvovirus: management by intrauterine transfusion
DOI:
https://doi.org/10.18041/2390-0512/biociencias.1.7842Keywords:
Fetal hydrops, parvovirus, intrauterine transfusionAbstract
Fetal hydrops is the abnormal accumulation of fluid in at least 2 fetal compartments. Its origin can be immune or non-immune. Parvovirus B19 is responsible for a significant part of non-immune hydrops cases. The fetal prognosis is poor with high mortality. We present a clinical case of a pregnant woman with a fetus affected by non-immune hydrops secondary to severe anemia after infection with parvovirus B19, managed by intrauterine transfusion.
Downloads
References
Derderian S, Jeanty C, Fleck S, Cheng L, Peyvandi S, Moon-Grady A, MacKenzie T. The many faces of hydrops. Journal of pediatric surgery, 2015; 50(1): 50-54.
Steurer M, Peyvandi S, Baer R, MacKenzie T, Li B, Norton M, Moon-Grady A. Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis—Insights from a Population-Based Dataset. The Journal of pediatrics, 2017; 187(1): 182-188.
Moreno C, Kanazawa T, Barini R, Nomura M, Andrade K, Gomes C, Cavalcanti D. Non‐immune hydrops fetalis: A prospective study of 53 cases. American Journal of Medical Genetics Part A, 2013; 161(12): 3078-3086.
De Jong E, Walther F, Kroes A, Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenatal diagnosis, 2011; 31(5): 419-425.
Xiong Y, Tan J, Liu Y, He Q, Li L, Zou K, Sun X. The risk of maternal parvovirus B19 infection during pregnancy on fetal loss and fetal hydrops: A systematic review and meta-analysis. Journal of Clinical Virology, 2019; 114(1): 12-20.
Jensen I, Thorsen P, Jeune B, Møller B, Vestergaard B. An epidemic of parvovirus B19 in a population of 3596 pregnant women: a study of sociodemographic and medical risk factors. BJOG: An International Journal of Obstetrics & Gynaecology, 2000; 107(5): 637-643.
Sarfraz A, Samuelsen S, Bruu A, Jenum P, Eskild A. Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case–control study within 35 940 pregnant women. BJOG: An International Journal of Obstetrics & Gynaecology, 2009; 116(11): 1492-1498.
Desai K, Brustman L. Parvovirus in pregnancy. Topics in Obstetrics & Gynecology, 2014; 34(8): 1-5.
Riipinen A, Väisänen E, Nuutila M, Sallmen M, Karikoski R, Lindbohm M, Söderlund-Venermo M. Parvovirus b19 infection in fetal deaths. Clinical infectious diseases, 2008; 47(12): 1519-1525.
Lassen J, Jensen A, Bager P, Pedersen C, Panum I, Nørgaard-Pedersen B, Melbye M. Parvovirus B19 infection in the first trimester of pregnancy and risk of fetal loss: a population-based case-control study. American journal of epidemiology, 2012; 176(9): 803-807.
Kempe A, Rösing B, Berg C, Kamil D, Heep A, Gembruch U, Geipel A. First‐trimester treatment of fetal anemia secondary to parvovirus B19 infection. Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2007; 29(2): 226-228.
Carraca T, Matias A, Brandão O, Montenegro N. Early signs of cardiac failure: a clue for parvovirus infection screening in the first trimester? Fetal diagnosis and therapy, 2011; 30(2): 150-152.
Cosmi E, Mari G, Delle Chiaie L, Detti L, Akiyama M, Murphy J, Abuhamad A. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. American journal of obstetrics and gynecology, 2002; 187(5): 1290-1293
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Biociencias
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
